Application of astilbin in aspect of preventing and treating Parkinson's disease

Abstract

The invention discloses an application of astilbin in an aspect of preventing and treating Parkinson's disease, and belongs to the technical field of medical neuropharmacology. The invention relates to a potential application of a dihydroflavonol glycoside compound, namely the astilbin, in preparing a medicine for the clinical treatment of the Parkinson's disease. According to the application, by establishing an animal model of the Parkinson's disease and through the comprehensive utilization of various research methods including ethology, immunology, biochemical indexes and the like, experiments prove that the medicine can improve dyskinesia symptom in a model mouse of the Parkinson's disease and can relieve the degeneration of dopaminergic neuron of substantia nigra pars compacta; and the astilbin, which is rich in raw material source and good in effect, has a certain development value and a certain prospect in clinical application.

Description

technical field

[0001] The invention relates to the application of astilbin in preventing and treating Parkinson's disease, and belongs to the technical field of medical neuropharmacology. Background technique

[0002] Parkinson's disease (PD) is the most common degenerative disease of the motor nervous system, the main clinical manifestations are: resting tremor, slowness of movement, unsteady standing and postural reflex disorder. The main lesions in the brain of patients with Parkinson's disease are the substantia nigra and striatum. The death and reduction of dopaminergic neurons in the substantia nigra compacta is the direct cause of the decrease in dopamine projected to the striatum. As the second largest neurodegenerative disease after Alzheimer's disease, the incidence and prevalence of Parkinson's disease increase sharply with age, and the prevalence rate reaches 1% among the elderly over 60 years old. People over the age of 85 account for 5%-6%. At present, the num...

Examples

Embodiment 1

[0025] Example 1: Establishment and grouping of animal models

[0026] Body weight 20-25g, 8 weeks old, male C57BL / 6 mice, were randomly divided into control group, MPTP model group (first give MPTP and then give normal saline), astilbin administration group (first give MPTP and then give astilbin ), 20 per group. Placed at 23±2°C, the lighting time is 12h / day, and the animals are given drugs after one week of adaptation to the environment. The MPTP model group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected with normal saline once a day for 7 consecutive days. The administration group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected astilbin (50 mg / kg) solution once a day for 7 consecutive days. The control group was given normal saline for 12 consecutive days. Then the behavior of mice was evaluated by pole climbing test, and then the content of dopamine in str...

technical field

[0001] The invention relates to the application of astilbin in preventing and treating Parkinson's disease, and belongs to the technical field of medical neuropharmacology. Background technique

[0002] Parkinson's disease (PD) is the most common degenerative disease of the motor nervous system, the main clinical manifestations are: resting tremor, slowness of movement, unsteady standing and postural reflex disorder. The main lesions in the brain of patients with Parkinson's disease are the substantia nigra and striatum. The death and reduction of dopaminergic neurons in the substantia nigra compacta is the direct cause of the decrease in dopamine projected to the striatum. As the second largest neurodegenerative disease after Alzheimer's disease, the incidence and prevalence of Parkinson's disease increase sharply with age, and the prevalence rate reaches 1% among the elderly over 60 years old. People over the age of 85 account for 5%-6%. At present, the num...

Examples

Embodiment 1

[0025] Example 1: Establishment and grouping of animal models

[0026] Body weight 20-25g, 8 weeks old, male C57BL / 6 mice, were randomly divided into control group, MPTP model group (first give MPTP and then give normal saline), astilbin administration group (first give MPTP and then give astilbin ), 20 per group. Placed at 23±2°C, the lighting time is 12h / day, and the animals are given drugs after one week of adaptation to the environment. The MPTP model group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected with normal saline once a day for 7 consecutive days. The administration group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected astilbin (50 mg / kg) solution once a day for 7 consecutive days. The control group was given normal saline for 12 consecutive days. Then the behavior of mice was evaluated by pole climbing test, and then the content of dopamine in str...

Images